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Abstract: Next to a persistent infection with high-risk human papillomavirus (HPV), molecular
changes are required for the development of cervical cancer. To identify which molecular alterations
drive carcinogenesis, we performed a comprehensive and longitudinal molecular characterization
of HPV-transformed keratinocyte cell lines. Comparative genomic hybridization, mRNA, and
miRNA expression analysis of four HPV-containing keratinocyte cell lines at eight different time
points was performed. Data was analyzed using unsupervised hierarchical clustering, integrated
longitudinal expression analysis, and pathway enrichment analysis. Biological relevance of identified
key regulatory genes was evaluated in vitro and dual-luciferase assays were used to confirm
predicted miRNA-mRNA interactions. We show that the acquisition of anchorage independence
of HPV-containing keratinocyte cell lines is particularly associated with copy number alterations.
Approximately one third of differentially expressed mRNAs and miRNAs was directly attributable to
copy number alterations. Focal adhesion, TGF-beta signaling, and mTOR signaling pathways were
enriched among these genes. PITX2 was identified as key regulator of TGF-beta signaling and inhibited
cell growth in vitro, most likely by inducing cell cycle arrest and apoptosis. Predicted miRNA-mRNA
interactions miR-221-3p_BRWD3, miR-221-3p_FOS, and miR-138-5p_PLXNB2 were confirmed in vitro.
Integrated longitudinal analysis of our HPV-induced carcinogenesis model pinpointed relevant
interconnected molecular changes and crucial signaling pathways in HPV-mediated transformation.
Keywords: microRNA; mRNA; CGH; cervical cancer; HPV; microarray; TGF-beta; PITX2
1. Introduction
Development of cervical cancer is a multi-step process initiated by a persistent infection with
a high-risk type of the human papillomavirus (HPV) [1]. Following infection of the basal epithelial
cells by HPV, a productive infection is established, which is characterized by the production of new
viral particles [2,3]. The expression of viral proteins is tightly linked to host cell differentiation and is
necessary for viral genome replication in differentiated cells. Aberrant expression of viral oncogenes E6
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and E7 in proliferating cells, however, leads to the abortion of the viral life cycle and triggers malignant
transformation. While E6 and E7 initiate and maintain transforming infections, additional molecular
changes in the host cell genome are required for the development of invasive cancer.
Molecular alterations associated with cervical carcinogenesis are of both genetic and epigenetic
nature and ultimately lead to aberrant expression of oncoproteins and tumor suppressors. Genome-wide
analyzes of cervical tissue specimens have led to the identification of numerous chromosomal
aberrations and differentially expressed coding and non-coding genes in cervical (pre)cancer [4–6].
As the sequential order of molecular changes as well as their causative relevance for cancer development
cannot be extrapolated from cross-sectional data, it has proven problematic to distil promising disease
markers and potential therapeutic targets from these observations.
In vitro cell line models of HPV-mediated transformation, in which primary keratinocytes
are transfected with HPV16 or HPV18, have been shown to faithfully mimic cervical cancer
development [7–9]. This offers the unique opportunity to study (epi)genetic alterations during
carcinogenesis. Integrative analysis of longitudinal data obtained from multiple molecular levels
allows for reconstruction of the sequential order in which molecular changes occur and is likely to result
in the identification of crucial molecular alterations that drive the carcinogenic process. Importantly,
HPV-transformed keratinocytes have previously been shown to provide useful model systems to
study chromosomal instability in cancer in general [10], indicating that insights in HPV-induced
transformation might not only provide a better understanding of cervical cancer development, but
could be applicable to other cancers, too.
Previous studies have demonstrated that HPV-induced transformation can be divided into four
stages (Figure 1a) [11,12]: an extended lifespan (1) is acquired as a result of E6 and E7 mediated inhibition
of tumor suppressor genes TP53 and RB1 [13]. Genetic instability induced by E6 and E7 subsequently
generates an immortal phenotype (2) usually associated with the activation of the telomerase enzyme
resulting from upregulation of TERT. During prolonged culturing of HPV-immortalized keratinocytes
additional (epi)genetic alterations accumulate that can eventually lead to anchorage-independent
growth (3), considered as proof for complete transformation in vitro [14,15], and tumorigenicity (4).
Here, we present the first comprehensive molecular profiling of HPV-induced carcinogenesis over
time. DNA copy number changes, mRNA, and miRNA expression were determined in four individual
HPV-transformed keratinocyte cell lines at eight different passages representing different stages of
HPV-induced transformation (hereafter referred to as time points). Integrative temporal analysis of
this unique longitudinal multi-level dataset allowed for the identification of relevant pathways and
associated key regulators as well as the prediction of miRNA-mRNA interactions in HPV-induced
transformation. The obtained results will greatly accelerate the identification of those molecular
alterations that are crucial to HPV-induced carcinogenesis and as such will likely provide highly
specific and sensitive disease markers. These are urgently needed to improve current cervical cancer
screening programs for the coming era, especially with the implementation of HPV-based screening
and HPV vaccination in more and more countries.
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Figure 1. Characterization of our longitudinal in vitro model system of human papillomavirus
(HPV)-induced transformation. (a) Anchorage-dependent (black) and -independent (red) time points
(T) of all four cell lines are shown in relation to the transformation process [16]. MiRNA microarrays of
cell line FK18A at T4 and T5 did not pass quality control and were therefore excluded from miRNA
analysis. Unsupervised hierarchical cluster results based on (b) DNA copy number, (c) overall mRNA
expression, and (d) overall miRNA [16] expression are shown for FK16A, FK16B, FK18A, and FK18B.
2. Results
2.1. Anchorage Independence Coincides with Marked Molecular Changes
To study the molecular events driving HPV-induced transformation, we investigated four
independent HPV-transformed keratinocyte cell lines at different stages during transformation. Copy
number changes, mRNA, and miRNA expression were determined in all four cell lines at six to eight
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different passages (time points) (Table 1). As described previously, the selected time points represent
distinct stages in HPV-induced transformation (Figure 1a) [16].
Table 1. Passage numbers included for all four HPV-transformed cell lines [16].
Time Point FK16A FK16B FK18A FK18B
T1 p18 p21 p19 p17
T2 p22 p22 p21 p18
T3 p39 p45 p47 p40
T4 p52 p51 p60 p52
T5 p109 p89 p92 p90
T6 p115 p102 p99 p98
T7 p206 p140 p148 p146
T8 p222 p169 p160 p164
FK16A and FK16B contain HPV16, whereas FK18A and FK18B contain HPV18. No shading: anchorage-dependent
cells; grey shading: anchorage-independent cells.
To obtain an unbiased overview of the observed molecular changes over time in the four cell
lines, we performed unsupervised clustering analysis of genomic as well as mRNA and miRNA
expression profiles. Chromosomal profiles of all four cell lines were separated almost perfectly based
on their ability to grow anchorage-independently (Figure 1b), which supports our previous observation
based on miRNA expression profiles (Figure 1d) [16]. Revealing a slightly less clear-cut separation,
a sub-cluster enrichment for either anchorage-dependent or anchorage-independent time points was
still noticeable for mRNA profiles (Figure 1c).
2.2. Approximately One Third of Differentially Expressed Genes is Associated with Copy Number Changes
To identify genes relevant to HPV-induced carcinogenesis, we performed integrative longitudinal
differential gene expression analysis, which also takes the genomic copy number into account [17].
In total, expression of 3642 mRNA genes and 106 mature miRNAs (corresponding to 118 miRNA
genes) was found to either increase or decrease consistently over time in at least three out of four
cell lines analyzed (Tables S1 and S2). An association with copy number was observed in 33.9% of
significant mRNAs (1233 genes, Table S1) and 32.2% of miRNA genes (38 genes, Table S2).
A technical validation of our microarray results was performed by qRT-PCR for three mRNAs
(DEK, DKK3, SLC25A36, Figure S1a) and five miRNAs (miR-100-5p, miR-103a-3p, miR-125b-5p,
miR-15b-5p, miR-221-5p, Figure S1b). Moreover, in vivo relevance of our findings was investigated for
those differentially expressed mRNAs and miRNAs for which in-house microarray data of cervical
tissue samples was available (mRNAs: 2661 out of 3642, miRNA: 39 out of 106). A concordant
significant pattern of up- or downregulation was observed from normal to CIN to SCC by Spearman
correlation for 24% of mRNAs and 49% of miRNAs, whereas 15% of mRNAs and 18% of miRNAs
exhibited an opposite expression pattern in tissues and the cell line model (Table S1 and S2).
2.3. Pinpointing Key Regulators in Enriched Pathways
Based on the unsupervised hierarchical cluster results we hypothesized that a substantial
proportion of the above described DNA copy number induced gene expression changes are involved
in the acquisition of anchorage independence. Indeed, three of the most significantly overrepresented
pathways among all DNA copy number associated genes (Table S3), namely focal adhesion (KEGG
hsa04510), TGF-beta (KEGG hsa04350), and mTOR signaling (KEGG hsa04150), are implicated in
processes underlying anchorage independence (i.e., anoikis resistance and induction of EMT) [18]. To
further investigate this notion, we translated our longitudinal data into pathway-based networks for
focal adhesion, TGF-beta signaling, and mTOR signaling (Table S3 and Materials and Methods section).
Data-driven longitudinal networks were built for all genes in the respective pathways taking copy
number into account and key regulators were identified (Table 2, Figure 2, Table S4).
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Figure 2. Pathway reconstruction. Inferred dynamic networks of the (a) focal adhesion, (b) mTOR
signaling, and (c) TGF-beta signaling pathways. Blue circles are the nodes of the network and represent
genes. The lines depict which genes’ mRNA expression level at the current time point, denoted by Yt,
affect the genes’ mRNA expression level at a future time point, denoted Yt + 1. Solid and dashed lines
indicate whether this relation is of a stimulating (positive) or suppressing (negative) nature, respectively.
For plotting purposes, genes with a total edge strength (sum of all absolute in and out connections of
the respective gene) <0.25 (or <1 for TGF-beta signaling) were excluded.
Table 2. Key regulators of selected pathways.
(a) Focal Adhesion (b) mTOR Signaling
Regulator Number ofRegulated Genes
Regulated Genes in
Pathway (%) Regulator
Number of
Regulated Genes
Regulated Genes in
Pathway (%)
TNN 72 36.0 RPS6KA2 18 34.6
LAMA4 40 20.0 IGF1 16 30.8
COL5A3 32 16.0 HIF1A 12 23.1
MYLPF 30 15.0 PRKAA2 4 7.7
MYL10 26 13.0 DDIT4 3 5.8
FYN 24 12.0 STK11 3 5.8
PDGFD 22 11.0 EIF4B 3 5.8
ITGA4 21 10.5 PIK3CD 2 3.8
COMP 17 8.5 PIK3R3 2 3.8
LAMA3 16 8.0 VEGFC 2 3.8
(c) TGF-Beta Signaling
Regulator Number ofRegulated Genes
Regulated Genes in
Pathway (%)
PITX2 45 52.9
ID4 34 40.0
LEFTY2 24 28.2
INHBA 22 25.9
BMP4 19 22.4
ID1 18 21.2
FST 15 17.6
AMHR2 10 11.8
COMP 10 11.8
TGFB2 7 8.2
2.4. TGF-Beta Pathway
TGFB1 has previously been shown to act as tumor suppressor during early stages of cervical
carcinogenesis, although it takes on a tumor promoting function at a later stage [19]. Here, we
identified PITX2 as key regulator of TGF-beta signaling (Table 2c). PITX2 was downregulated in all
four keratinocyte cell lines (Figure 3a) and this was concordant with our in-house tissue data (normal
to CIN2/3 to SCC, Figure 3b).
To investigate the functional relevance of PITX2, a PITX2 expression vector was transduced in late
FK18B cells. Cell growth analysis demonstrated a decrease in cell viability after three days of PITX2
overexpression compared to empty vector (GFP only) transduced FK18B cells (Figure 3c,d). PITX2 has
previously been shown to cause G0/G1 arrest in HPV18-positive HeLa cells through accumulation of
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TP53 and CDKN1A (p21) [20,21]. In line with this, we found elevated TP53 and CDKN1A protein
levels in PITX2 overexpressing FK18B cells (Figure 3d). To elucidate whether the observed growth
reduction in PITX2 overexpressing cells is caused by TP53/CDKN1A-mediated cell cycle arrest or
apoptosis, we further analyzed known marker proteins CDKN1B (p27), PCNA, and cleaved CASP3.
Even though there was no change in PCNA levels upon PITX2 overexpression, increased levels of
CDKN1B and cleaved CASP3 suggested that reduced cell viability in PITX2 overexpressing cells is
associated to both cell cycle arrest and apoptosis (Figure 3d).
Figure 3. PITX2 acts as tumor suppressor in HPV-induced transformation. (a) PITX2 expression in
HPV-transformed keratinocyte cell lines. Using our tigaR method, a model without (red continuous
line) and with copy number effect (blue discontinuous line) was fitted [17]. Similarity between the fitted
models indicates that differential PITX2 expression is not copy number-driven. (b) PITX2 expression in
mRNA microarray data obtained from normal HPV-positive cervical epithelium (Normal), high-grade
precancerous lesions (CIN2/3), and squamous cell carcinomas (SCC). Boxplots show medians with
lower and upper quartiles, and range whiskers. * p < 0.05, ** p < 0.005, according to the Wilcoxon
rank-sum test. (c,d) Late FK18B cells (ca. passage 190) were transduced with an empty LeGO-iG2 vector
or a LeGO-iG2-PITX2 construct. (c) FACS analysis: Mean and standard deviation of two independent
experiments are shown. (d) Western blot analysis. Cells were harvested 72 h after transduction. Cells
treated with etoposide were included as positive control for TP53/CDKN1A signaling.
2.5. Identification of Potential miRNA-mRNA Target Interactions
Using our developed tigaR framework we next investigated the relation between miRNA and
mRNA expression in a longitudinal fashion. For this analysis, we only included miRNAs for which
altered expression was not contradictory to the pattern observed in the tissue specimens (n = 86). When
restricting the analysis to miRNA-mRNA pairs showing significant expression changes over time in
the opposite direction, 634 interactions between 27 miRNAs and 372 mRNAs were identified (Table S5).
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For the verification of the 634 potential interactions, we used three up-to-date publicly available target
prediction databases: RNA22 v2.0, miRDB v5, and TargetScan v7 [22–24]. Four interactions were
predicted by all three databases (Table S5).
To validate our miRNA target prediction, the four miRNA-mRNA interactions that were
predicted by all three databases, i.e., miR-138-5p_PLXNB2, miR-221-3p_BRWD3, miR-221-3p_FOS,
and miR-30a-3p_PECR, were selected. For all four miRNA-mRNA pairs, mRNA expression increased
and miRNA expression decreased with increasing passage number in at least three out of four cell
lines. Ectopic overexpression of the respective miRNA in late passage FK18B cells resulted in reduced
expression levels of the predicted mRNA targets BRWD3, PECR, and PLXNB2 (Figure 4a–d). Ectopic
overexpression of miR-221-3p surprisingly led to 40% increase of FOS expression in FK18B.
Figure 4. Confirmation of miRNA-mRNA interactions. Predicted miRNA-mRNA interactions (a)
miR-221-3p_BRWD3, (b) miR-221-3p_FOS, (c) miR-30a-3p_PECR, and (d) miR-138-5p_PLXNB2 were
investigated using mRNA expression analysis and dual-luciferase reporter assays. Left panel: Effects
of ectopic expression of the miRNA on the expression level of its predicted mRNA target. Expression
levels were determined by qRT-PCR in late passage FK18B cells (ca. passage 190) transfected either with
a negative control (cntr#2) or with the respective miRNA mimic. Data was normalized to SNRPA. Mean
and standard deviation of two technical replicates are shown. Right panel: Dual-luciferase reporter
assay to confirm direct interaction between the miRNA and its predicted target mRNA. HEK293
cells were transiently transfected with a negative control (cntr#1) or the respective miRNA mimic in
combination with either an empty pmiRGLO vector, a pmiRGLO construct containing the predicted
binding site (pmiRGLO-predicted target-UTR), or a pmiRGLO construct containing a mutated binding
site (pmiRGLO-predicted target-UTR_mut). MiRNA, UTR, and binding sites are indicated in the lower
panel. Mean and standard deviation of three technical replicates are shown. * p < 0.05, ** p < 0.005.,
according to the two-sided Student’s t-test.
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Next, dual-luciferase assays were performed to investigate whether the effects of miRNAs on
their target mRNAs are the result of direct interactions. As shown in Figure 4a, co-transfection
of pmiRGLO-BRWD3-UTR and ectopic miR-221-3p in HEK293 cells decreased luciferase activity
compared to either co-transfection of pmiRGLO-BRWD3-UTR with a non-targeting control sequence
or the empty pmiRGLO vector with ectopic miR-221-3p. Directed mutagenesis of the predicted
miR-221-3p seed sequence (pmiRGLO-BRWD3-UTR_mut) abolished the reduction in luciferase activity
observed with the wild type vector (Figure 4a). Likewise, a direct interaction between miR-221-3p and
the cFOS 3’UTR could be demonstrated (Figure 4b). Luciferase activity of a pmiRGLO-PECR-UTR
construct was comparable to that of the empty pmiRGLO vector in the presence of ectopic miR-30a-3p
or a non-targeting control sequence, suggesting that the observed reduction in PECR mRNA levels upon
ectopic overexpression of miR-30a-3p is an indirect effect (Figure 4c). Interestingly, PLXNB2 has two
predicted miR-138-5p binding sites in the 3’UTR. Luciferase activity of the pmiRGLO-PLXNB2-UTR
vector was reduced in the presence of miR-138-5p compared to the empty vector (Figure 4d). Mutation
of the first binding site significantly restored luciferase activity, while mutation of the second binding
site alone had almost no effect. The largest and most significant restoration of luciferase activity was
obtained when both binding sites were mutated.
Interestingly, ectopic expression of miR-30a-3p and miR-138-5p decreased anchorage-independent
growth of late passage FK18B cells as measured on ultra-low attachment plates (Figure 5). No reduction
in cell viability was observed on normal, adherent plates, suggesting involvement of these miRNAs
specifically in anchorage independence.
Figure 5. Effect of miRNAs on adherent and anchorage-independent growth of late passage FK18B
cells. Cell viability of late passage FK18B cells upon ectopic expression of miR-221-3p, miR-30a-3p,
and miR-138-5p was measured in adherent tissue culture coated plates and ultra-low attachment
plates and standardized against miRNA mimic negative control #1. Mean and standard errors of three
independent experiments are shown.
3. Discussion
We here present one of the most extensive studies characterizing HPV-induced transformation
in a longitudinal fashion. Unsupervised hierarchical clustering of our copy number data separated
nearly perfectly between anchorage-dependent and -independent passages of HPV-transformed cells,
demonstrating the importance of chromosomal alterations in the acquisition of anchorage independence.
Moreover, we show that differential expression of a considerable fraction of mRNAs and miRNAs is
directly attributable to copy number changes of their respective genes. Pathway enrichment analysis
on copy number affected mRNAs identified focal adhesion, mTOR signaling, and TGF-beta signaling
as altered pathways in HPV-induced carcinogenesis. The biological significance of these findings
is supported by functional evidence for PITX2, a key regulator of TGF-beta signaling, and novel
miRNA-mRNA interactions. Anchorage-independent cell growth is a hallmark of transformation
in vitro [14,15]. While loss of appropriate cell-cell and cell-matrix interactions leads to aberrant integrin
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signaling and eventually detachment-induced cell death (anoikis) in healthy epithelial cells, cancerous
epithelial cells overcome anoikis by epithelial-to-mesenchymal transition (EMT), activation of survival
and proliferation pathways, or temporary dormancy [25]. Strikingly, the focal adhesion, mTOR
signaling, and TGF-beta signaling pathways identified in present study are implicated in anoikis
resistance and induction of EMT [18,26].
TGFB1 has been reported to exert a tumor inhibiting function in early stages of cervical
carcinogenesis, while it plays an oncogenic role at a later stage by promotion of EMT and metastasis,
induction of angiogenesis, and escape from immune surveillance [19]. In line with this, expression
of TGFB1 was found to be downregulated in cervical precancerous lesions compared to normal
epithelium although it is increased in cervical cancers [27,28]. This TGF-beta paradox is not unique to
cervical carcinogenesis but has been recognized in many other cancers as well [29]. An analysis of
178 cervical carcinomas by The Cancer Genome Atlas (TCGA) network found recurrent deletions of
TGF-beta receptor 2 (TGFBR2, 3p24.1) and SMAD4 (18q21.2) in 36% and 28% of analyzed samples,
respectively [30]. In accordance, downregulation of both TGFBR2 and SMAD4 was related to copy
number loss in our cell line data (Table S1). Moreover, the TCGA network identified common somatic
mutations in the TGF-beta pathway for TGFBR2, SMAD4, CREBBP, and EP300 [30]. These mutations
are of an inactivating nature and are believed to deactivate growth-suppressive and pro-apoptotic
functions of TGF-beta, leading to a more tumorigenic phenotype.
In a previous study, we reported that the presence of TGFB1 reduced the growth rates of
mortal and early immortal FK16A and FK18B cells, but not of late immortal FK16A and FK18B
cells, in a SMAD2/SMAD4-independent fashion [31]. Similarly, Creek and colleagues showed that
HPV16-transformed cells become insensitive to TGFB1 with increasing passaging and demonstrated
that TGFB1 promotes EMT and cell migration [32–34]. A recent integrative screen comparing
transcriptome and proteome data of HPV16 E6E7 expressing keratinocytes to non-HPV expressing
keratinocytes confirmed that TGFB1 plays a regulatory role in HPV-induced carcinogenesis [35]. Here,
our extensive longitudinal pathway analysis identified PITX2 (pituitary homeobox 2) as key regulator
of TGF-beta signaling during cervical carcinogenesis. We show that elevated PITX2 expression induces
apoptosis and cell cycle arrest, indicating that downregulation of PITX2 is important for the survival of
HPV-transformed keratinocytes. In line with our results, PITX2 has been shown to cause cell cycle
arrest through accumulation of TP53 and CDKN1A in HeLa cells [20,21]. This is achieved through
binding of the HPV E6 protein by PITX2 and the subsequent inhibition of TP53 degradation [20].
Moreover, PITX2 has been described as transcriptional activator of CDKN1A in other tissues such
as the dental epithelium and neural stem cells [36,37]. Besides an effect on cell growth, others have
observed decreased migration upon PITX2 overexpression [20]. Wei and Adelstein showed that PITX2
activates the Rho GTPases RAC1 and RHOA, causing changes to the actin-myosin cytoskeleton thereby
reducing cell adhesion and increasing cell motility [20]. Interestingly, our pathway reconstruction also
identified RHOA as PITX2 target, as well as ROCK2 and THBS1, two other genes known to be involved
in cell adhesion and motility. Future studies on the involvement of PITX2 in growth inhibition, cell
cycle, migration, and invasion during HPV-induced transformation are therefore warranted.
The tumor suppressive role of PITX2 in cervical cancer development is further supported by our
previously published whole methylome data showing that the PITX2 promoter is highly methylated in
high passages of our four cell lines but not in primary donor keratinocytes [16]. PITX2 hypermethylation
has been described as a promising prognostic biomarker in cervical cancer as well as breast cancer,
head and neck squamous cell carcinoma, and prostate cancer [38–41].
Besides studying the effect of copy number aberrations on gene expression, the tigaR framework
also proved suitable for the identification of temporal miRNA-mRNA interactions [17]. Opposed to
BRWD3 and PLXNB2 being downregulated upon overexpression of their validated miRNA interaction
partner, FOS expression increased upon miR-221-3p overexpression. This observation is potentially
caused by the high ectopic levels of miR-221-3p in our experiments, which may result in an indirect
effect of miR-221-3p on FOS expression via other miR-221-3p targets. Under physiological conditions,
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we do not observe this indirect effect as illustrated by the opposing expression directions of FOS
(upregulated) and miR-221-3p (downregulated) over time in our cell line model as well as during
progression in cervical tissue specimens. In our cell line model, all investigated target mRNAs were
upregulated with increasing passages, suggesting oncogenic roles for these genes. While little is known
about the functional involvement of BRWD3 and PECR in human cancers, an enrichment of FOS as
part of a heterodimer with JUN has previously been linked to anchorage-independent cell growth in
our HPV-transformed cell lines as well as HeLa [42,43]. Moreover, PLXNB2 has been described to act
as oncogene in ovarian cancer cells, where a knock-down of PLXNB2 led to decreased cell viability
and invasion [44]. We demonstrate that miR-30a-3p and miR-138-5p reduce anchorage-independent
cell growth of late passage FK18B cells, indicating their functional role in anchorage independence.
Additional studies investigating the exact functional roles of the here identified miRNA-mRNA pairs
in cervical carcinogenesis might provide valuable therapeutic targets in the future.
4. Materials and Methods
4.1. Cell Lines and Clinical Specimens
Establishment and culture of the HPV16- (FK16A and FK16B) and HPV18- (FK18A and FK18B)
immortalized keratinocyte cell lines has been described previously [7]. Renal epithelium cell
line HEK293 was authenticated by STR testing using the Powerplex16 System (Promega, Leiden,
The Netherlands) and cultured as described previously [45]. From all four HPV-immortalized
keratinocyte cell lines eight passages (Table 1), including both anchorage-dependent (no shading) and
anchorage-independent (grey shading) cells, were selected.
4.2. RNA and DNA Isolation
Total RNA was isolated using TRIzol Reagent according to the manufacturer’s instructions (Thermo
Fisher Scientific, Bleiswijk, The Netherlands). RNA integrity was determined by gel electrophoresis.
Total DNA was isolated by standard proteinase K digestion followed by phenol-chloroform
purification [46].
4.3. Microarrays for DNA, mRNA, and miRNA Profiling
4.3.1. CGH Arrays
To determine genome-wide chromosomal profiles, DNA was hybridized onto comparative
genomic hybridization (CGH) microarrays (SurePrint G3 human CGH microarray 4x180K; Agilent
Technologies, Santa Clara, CA, USA) according to the manufacturer’s instructions. CGH microarray
data are available from the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
through series accession number GSE138724.
4.3.2. mRNA Arrays
Global mRNA expression profiles were generated using whole human genome oligo
microarrays (G4112F, mRNA 4 × 44K; Agilent Technologies) following the manufacturer’s
instructions. High-resolution mRNA expression data are available from GEO through series accession
number GSE138079.
4.3.3. miRNA Arrays
Global miRNA expression profiles were determined using human miRNA microarrays (Sureprint
G3 human v16 miRNA 8 × 60K; Agilent Technologies) according to the manufacturer’s instructions.
These arrays contain in situ synthesized 60-mer oligonucleotides representing 1205 human miRNAs
based on the Sanger miRBase release 16. Microarrays for two passages of FK18A (passage 60 and
92, i.e., T4 and T5) failed subsequent quality control and were excluded from analysis. Microarray
Cancers 2020, 12, 700 11 of 17
data have previously been published and are available from GEO through series accession number
GSE78279 [16].
4.3.4. Expression Profiling on Tissue Specimens
To confirm in vivo relevance of our cell line data, miRNA, and mRNA expression was analyzed in
microarray data obtained from cervical tissue specimens. Global miRNA profiles were obtained from
normal HPV-positive cervical epithelium (n = 10), high-grade precancerous lesions (CIN2/3, n = 18),
and squamous cell carcinomas (SCC, n = 10). Data is available from GEO through series accession
number GSE30656 [47]. The same tissue specimens were used to determine global mRNA expression
profiles using whole human genome oligo microarrays (G4112F, mRNA 4 × 44K; Agilent Technologies).
Three CIN2/3 did not pass quality control and were excluded from analysis. High-resolution mRNA
expression data obtained from cervical tissue samples are available from GEO through series accession
number GSE138080. Tissue samples were used in an anonymous fashion in accordance with the Code
for Proper Secondary Use of Human Tissues in the Netherlands as formulated by the Dutch Federation
of Medical Scientific Organizations (www.federa.org).
4.4. Data Pre-Processing and Analysis
4.4.1. Pre-Processing and Matching
DNA copy number data were pre-processed employing median normalization and segmented
using the circular binary segmentation method [48]. mRNA gene expression data were background
corrected and between array normalization was performed using the robust quantile method [49,50].
Resulting gene expression intensities were transformed using variance stabilizing transformation [51].
MiRNA gene expression data were processed similarly but without background correction.
Prior to integrative downstream analysis, mRNA and miRNA gene transcripts were matched
to DNA copy number data based on the genes’ respective chromosomal locations (genomic build
GRCh37/hg19) using the overlapPlus matching procedure described in Van Wieringen et al. [52].
4.4.2. Cluster Analysis
Unsupervised hierarchical clustering was performed per cell line on complete mRNA/miRNA
expression profiles to explore the overall similarities and differences in expression patterns using
maximum as distance measure. The R-package WECCA was used for unsupervised hierarchical
clustering of samples based on their DNA copy number profiles per cell line [53]. All dendrograms
were constructed using Ward’s linkage as it yields compact and well-separated clusters.
4.4.3. Differential Expression Analysis
To identify m(i)RNA genes with temporal differential expression and to study the association
between gene expression and underlying copy number changes, the methodology presented in
Miok et al. was employed [17]. Temporal gene expression analysis was performed with a common
spline for the cell lines, to identify consistently altered genes over time at a 5% false-discovery rate
(FDR). The same methodology was used to investigate associations between mRNA and miRNA
gene expression data over time [17]. From this analysis, significantly associated miRNA-mRNA gene
pairs with a negative regression parameter were selected. Identified miRNA-mRNA interactions were
verified by three independent databases: RNA22 v2.0, miRDB v5, and TargetScan v7 [22–24]. RNA22
v2.0 uses conserved sequence features among miRNAs, so-called patterns, to identify binding site
hotspots in the 3’ untranslated region (3’UTR) of mRNAs [22]. The identified putative binding sites are
then associated to individual miRNAs independent of their seed sequences. miRDB and TargetScan
are both based on target prediction features such as miRNA seed conservation or the mRNA sequence
flanking the binding site [23,24]. While the MirTarget2 algorithm employed by miRDB uses a support
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vector machine framework, TargetScan employs a linear regression model. In both cases, prediction
features were selected and weighted based on large experimental datasets.
4.4.4. Network Modeling
For network enrichment analysis, 118 potentially relevant pathways stored in the KEGG repository
were considered (Table S1) [54]. Enrichment analysis showed significant overrepresentation of 21
pathways within the copy number related differentially expressed mRNAs (chi-square test with FDR
correction). From these 21 pathways, focal adhesion (KEGG hsa04510), TGF-beta signaling (KEGG
hsa04350), and mTOR signaling (KEGG hsa04150) were selected for subsequent pathway reconstruction
analysis based on the following criteria: (1) total number of genes in pathway is between 50 and 200
(requirement for downstream pathway reconstruction), (2) more than 5% of genes within the pathway
showed copy number induced differential expression. Although the B-cell receptor signaling pathway
(hsa04662) and cell cycle (hsa04110) also met these criteria, they were not investigated further. This
analysis aimed to identify hub genes, which represent possible key regulators of the pathway in the
given context. For this purpose, mRNA gene expression data from the experiment was mapped to the
pathways as defined by the KEGG repository and the vector autoregressive model with time-varying
DNA copy number was employed [54,55]. This model allows to identify both temporal (signals
propagated over time) and contemporaneous (signal propagated among the genes) interactions among
the genes. This integrative methodology allows identification of the ‘within-level’ relationship in the
mRNA gene levels as well as relations between different molecular levels [55,56].
4.5. Quantitative Reverse Transcription-PCR (qRT-PCR)
4.5.1. mRNA qRT-PCR
To determine expression levels of BRWD3, DEK, DKK3, FOS, PECR, PLXNB2, SNRPA, and
SLC25A36, cDNA was synthesized from 200 ng total RNA template using specific reverse primers
(Table S6a). All primer pairs were intron-flanking with an exception for mono-exonic FOS. For analysis
of FOS expression, RNA samples were therefore treated with RQ1 DNase (Promega) prior to reverse
transcription. The resulting cDNA was used for SYBR Green qPCR on the ABI7500 Fast Real-Time PCR
System (Thermo Fisher Scientific). Specificity of the PCR reaction was determined generating melting
curves for each reaction. Each 25 µL PCR reaction contained 12.5 µL 2× SYBR Green master mix
(Thermo Fisher Scientific), 0.5 µM forward and reverse primers, and 2.5 µL cDNA. Cycle conditions
used were according to the manufacturer’s instructions. Data were normalized so SNRPA using the
2−∆Ct method [57].
4.5.2. MiRNA qRT-PCR
Expression of miR-100-5p, miR-103a-3p, miR-125b-5p, miR-138-5p, miR-15b-5p, miR-21-3p,
miR-221-3p, miR-221-5p, and U75 were measured using TaqMan microRNA assays (000437, 000439,
000449, 002284, 000390, 002438, 000524, 002096, 001219; Thermo Fisher Scientific). The TaqMan
microRNA Reverse Transcription kit (Thermo Fisher Scientific) was used for cDNA synthesis from
10 ng total RNA template according to the manufacturer’s instructions. Quantitative PCR reactions
were performed on the ABI7500 Fast Real-Time PCR System (Thermo Fisher Scientific). Each 10 µL
qPCR reaction contained 5 µL TaqMan® Universal Master Mix II (Thermo Fisher Scientific), 0.5 µL
miRNA specific TaqMan assays, 3.5 µL H2O, and 1 µL cDNA. Cycle conditions for cDNA synthesis and
PCR were used according to the manufacturer’s protocols. miRNA expression data were normalized
to U75 using the 2−∆Ct method [57].
4.6. Viral Transduction and Flow Cytometry
The coding sequence of PITX2 transcript variant 2, amplified by Phusion High-Fidelity PCR
(New England Biolabs (NEB), Ipswich, MA, USA), was cloned into the lentiviral vector LeGO-iG2 [58]
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(Addgene, Teddington, UK) via the pcDNA3.1(+) Mammalian Expression Vector (Thermo Fisher
Scientific) using HindIII and NotI restriction sites. For primer sequences please refer to Table S6b.
Restriction enzymes were purchased from NEB. For virus production, HEK293 cells were transfected
with lentiviral packaging plasmids pRSV-rev, pCMV-VSV-G, and pMDLg/RRE together with LeGO-iG2
empty vector or LeGO-iG2-PITX2 using polyethylenimine (PEI; Sigma-Aldrich, St. Louis, MO, USA).
Late passage FK18B cells (ca. passage 190) were transduced with lentivirus using polybrene (Thermo
Fisher Scientific) for 24 h. Cells were harvested for RNA 72 h after transduction. Analysis of GFP
expression was performed on a FACS-Calibur flow cytometer (BD Biosciences, Breda, The Netherlands)
equipped with the CellQuest Pro data acquisition and analysis software. Two independent experiments
were performed.
4.7. Protein Lysis and Western Blot Analysis
Whole cell lysates were prepared using the RIPA Lysis Buffer System (Santa Cruz Biotechnology,
Dallas, TX, USA) with benzonase (Sigma-Aldrich) 72 h after transduction. Twenty-five micrograms of
protein was fractionated on 8–16% precast polyacrylamide gels (Bio-Rad, Hercules, CA, USA) and
transferred to a nitrocellulose membrane. Western blots were incubated with Anti-ACTB (1:1000,
rabbit, Cell Signaling Technologies, Danvers, MA, USA), Anti-Cleaved CASP3 (1:1000, rabbit, BD
Biosciences), Anti-p21 (CDKN1A; 1:1000, mouse, Sigma-Aldrich), Anti-p27 (CDKN1B; 1:1000, mouse,
BD Biosciences), Anti-PCNA (1:1000, mouse, Dako), Anti-PITX2 (1:1000, rabbit, Abcam, Cambridge,
UK), or Anti-TP53 (1:1000, mouse, Dako, Glostrup, Denmark). Antibody binding was visualized using
goat-α-rabbit IRDye 680RD and goat-α-mouse IRDye 800CW (both LI-COR Biosciences, Lincoln, NE,
USA). As positive control for TP53/CDKN1A signaling, FK18B cells treated with 50 µM etoposide
(Sigma-Aldrich) for three hours were included in the Western blot.
4.8. MiRNA Transfection and Luciferase Dual-Reporter Assays
Late passage FK18B cells (ca. passage 190) were transiently transfected with 30nM miRIDIAN
microRNA mimics for miR-138-5p, miR-21-3p, miR-221-3p, and negative control #2 (C-300605-05,
C-301023-01, C-300578-05, CN-002000-01; Horizon Discovery, Cambridge, UK) using Dharmafect 1
(Horizon Discovery) for 22 h according to the manufacturer’s instructions. Cells were harvested for
RNA 48 h after transfection. Each experiment was carried out three times.
The predicted 3’UTR binding sites of BRWD3, FOS, PECR, and PLXNB2 amplified by Phusion
High-Fidelity PCR (NEB) were cloned into the pmirGLO Dual-Luciferase miRNA Target Expression
Vector (Promega) using the SacI (NEB) and XhoI (NEB) restriction sites. Predicted miRNA binding
sites were mutated using the Q5 Site-Directed Mutagenesis Kit (NEB) according to the manufacturer’s
instructions (Figure 4a–d). Primer sequences are listed in Table S6c–d. HEK293 were seeded in triplicate
in 96-well plates (7500 cells/well) and co-transfected with 6.67 nM mimics and 20 ng pmiRGLO vector
the following day. Firefly luciferase activity was measured using the Dual-Glo Luciferase Assay
(Promega) according to the manufacturer’s instructions 48 h after transfection. Renilla luciferase activity
was determined as internal control and used for normalization. Each experiment was carried out
three times.
4.9. MiRNA Transfection and Cell Viability Assays
Late passage FK18B cells (passage 220) were transfected with miRNA mimics using a reverse
transfection method. Briefly, the miRNA mimic/transfection reagent complexes were made by adding
miRNA mimics for miR-138-5p, miR-21-3p, miR-221-3p, negative control #1, and UBB siRNA (positive
control; C-300605-05, C-301023-01, C-300578-05, CN-001000-01, L-003290-00; Horizon Discovery) and
Dharmafect 4 transfection reagent (Horizon Discovery) to tissue culture coated plates and ultra-low
attachment plates (Corning, New York, NY, USA). Subsequently, cells were added and cell viability was
measured after 72 h of incubation using the luminescent CellTiter-GLO 3D assay (Promega) according
to the manufacturer’s protocol. Each experiment was carried out three times.
Cancers 2020, 12, 700 14 of 17
5. Conclusions
In conclusion, we present a unique longitudinal multi-level dataset on HPV-induced
transformation. Using state-of-the-art analysis tools, we identified key pathway regulators and novel
miRNA-mRNA interactions relevant to the carcinogenic process. Our results highlight the importance
of chromosomal alterations in the acquisition of anchorage independence during carcinogenesis.
Additional functional studies on the identified key pathway regulators and differentially expressed
m(i)RNAs might yield potential therapeutic targets and disease markers in the future.
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